首页> Current Alzheimer research> Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease.

Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease.

导出 OA

翻译打印收藏纠错

第一作者： Michael,Hull

第一单位： Clinic for Geriatric Psychiatry, Center for Psychiatry Emmendingen, Neubronnstraße 25, D-79312 Emmendingen. Germany.

作者： Michael,Hull ^[1] ; Carl,Sadowsky ^[2] ; Heii,Arai ^[3] ; Ghislaine,Le Prince Leterme ^[4] ; Ann,Holstein ^[5] ; Kevin,Booth ^[5] ; Yahong,Peng ^[5] ; Tamotsu,Yoshiyama ^[6] ; Hideo,Suzuki ^[6] ; Nzeera,Ketter ^[7] ; Enchi,Liu ^[7] ; J Michael,Ryan ^[5]

作者单位： Clinic for Geriatric Psychiatry, Center for Psychiatry Emmendingen, Neubronnstraße 25, D-79312 Emmendingen. Germany. ^[1] Premiere Research Institute, Palm Beach Neurology, Nova SE University, 4631 North Congress Ave., Suite 200, West Palm Beach, FL 33407, United States. ^[2] Department of Psychiatry & Behavioral Science, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. ^[3] Pfizer Global Research and Development, 23-25 avenue du Docteur Lannelongue, 75668 Paris cedex 14. France. ^[4] Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, United States. ^[5] Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151- 8589, Japan. ^[6] Janssen Research and Development, 3210 Merryfield Row, San Diego, CA 92121, United States. ^[7]

关键词 Alzheimer’s disease amyloid plaques amyloid-beta antibody immunotherapy vaccine